Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
OSUR's Cash to Debt is ranked higher than
99% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. OSUR: No Debt )
OSUR' s 10-Year Cash to Debt Range
Min: 1.19   Max: No Debt
Current: No Debt

Equity to Asset 0.84
OSUR's Equity to Asset is ranked higher than
93% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.57 vs. OSUR: 0.84 )
OSUR' s 10-Year Equity to Asset Range
Min: 0.69   Max: 0.94
Current: 0.84

0.69
0.94
Interest Coverage No Debt
OSUR's Interest Coverage is ranked higher than
89% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.94 vs. OSUR: No Debt )
OSUR' s 10-Year Interest Coverage Range
Min: 13.49   Max: 9999.99
Current: No Debt

13.49
9999.99
F-Score: 6
Z-Score: 7.28
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.51
OSUR's Operating margin (%) is ranked higher than
62% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.43 vs. OSUR: -4.51 )
OSUR' s 10-Year Operating margin (%) Range
Min: -400   Max: 10.92
Current: -4.51

-400
10.92
Net-margin (%) -4.33
OSUR's Net-margin (%) is ranked higher than
63% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.28 vs. OSUR: -4.33 )
OSUR' s 10-Year Net-margin (%) Range
Min: -637.93   Max: 39.57
Current: -4.33

-637.93
39.57
ROE (%) -2.90
OSUR's ROE (%) is ranked higher than
62% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. OSUR: -2.90 )
OSUR' s 10-Year ROE (%) Range
Min: -104.65   Max: 28.22
Current: -2.9

-104.65
28.22
ROA (%) -2.51
OSUR's ROA (%) is ranked higher than
62% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.93 vs. OSUR: -2.51 )
OSUR' s 10-Year ROA (%) Range
Min: -96.15   Max: 25.09
Current: -2.51

-96.15
25.09
ROC (Joel Greenblatt) (%) -16.70
OSUR's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.59 vs. OSUR: -16.70 )
OSUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -243.48   Max: 53.74
Current: -16.7

-243.48
53.74
Revenue Growth (3Y)(%) 2.80
OSUR's Revenue Growth (3Y)(%) is ranked higher than
70% of the 263 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. OSUR: 2.80 )
OSUR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.7   Max: 65.1
Current: 2.8

-2.7
65.1
EPS Growth (3Y)(%) -25.00
OSUR's EPS Growth (3Y)(%) is ranked higher than
55% of the 229 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. OSUR: -25.00 )
OSUR' s 10-Year EPS Growth (3Y)(%) Range
Min: -56.3   Max: 35.7
Current: -25

-56.3
35.7
» OSUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

OSUR Guru Trades in Q1 2014

Chuck Royce 525,000 sh (+17.58%)
PRIMECAP Management 2,163,600 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 233,800 sh (-12.53%)
Louis Moore Bacon 100,000 sh (-33.33%)
» More
Q2 2014

OSUR Guru Trades in Q2 2014

Paul Tudor Jones 16,570 sh (New)
Jim Simons 436,679 sh (+86.77%)
Chuck Royce 680,821 sh (+29.68%)
Louis Moore Bacon 100,000 sh (unchged)
PRIMECAP Management 2,025,400 sh (-6.39%)
» More
Q3 2014

OSUR Guru Trades in Q3 2014

Jim Simons 536,503 sh (+22.86%)
Chuck Royce 686,321 sh (+0.81%)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
PRIMECAP Management 2,022,900 sh (-0.12%)
» More
Q4 2014

OSUR Guru Trades in Q4 2014

Paul Tudor Jones 38,691 sh (New)
PRIMECAP Management 2,022,900 sh (unchged)
Jim Simons 476,803 sh (-11.13%)
Chuck Royce 607,221 sh (-11.53%)
» More
» Details

Insider Trades

Latest Guru Trades with OSUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 166.67
OSUR's Forward P/E is ranked higher than
62% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.73 vs. OSUR: 166.67 )
N/A
P/B 2.30
OSUR's P/B is ranked higher than
77% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. OSUR: 2.30 )
OSUR' s 10-Year P/B Range
Min: 0.96   Max: 6.43
Current: 2.3

0.96
6.43
P/S 3.53
OSUR's P/S is ranked higher than
53% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.32 vs. OSUR: 3.53 )
OSUR' s 10-Year P/S Range
Min: 1.53   Max: 9.29
Current: 3.53

1.53
9.29
PFCF 96.10
OSUR's PFCF is ranked higher than
67% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 97.29 vs. OSUR: 96.10 )
OSUR' s 10-Year PFCF Range
Min: 25.48   Max: 99999999.99
Current: 96.1

25.48
99999999.99
POCF 56.75
OSUR's POCF is ranked higher than
71% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.60 vs. OSUR: 56.75 )
OSUR' s 10-Year POCF Range
Min: 20.45   Max: 94.9
Current: 56.75

20.45
94.9
Current Ratio 4.96
OSUR's Current Ratio is ranked higher than
90% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. OSUR: 4.96 )
OSUR' s 10-Year Current Ratio Range
Min: 2.4   Max: 14.78
Current: 4.96

2.4
14.78
Quick Ratio 4.36
OSUR's Quick Ratio is ranked higher than
90% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. OSUR: 4.36 )
OSUR' s 10-Year Quick Ratio Range
Min: 1.97   Max: 14.11
Current: 4.36

1.97
14.11
Days Inventory 123.27
OSUR's Days Inventory is ranked higher than
74% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 133.28 vs. OSUR: 123.27 )
OSUR' s 10-Year Days Inventory Range
Min: 49.25   Max: 296.56
Current: 123.27

49.25
296.56
Days Sales Outstanding 55.33
OSUR's Days Sales Outstanding is ranked higher than
83% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.74 vs. OSUR: 55.33 )
OSUR' s 10-Year Days Sales Outstanding Range
Min: 38.83   Max: 84.73
Current: 55.33

38.83
84.73

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.60
OSUR's Price/Net Cash is ranked higher than
96% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. OSUR: 5.60 )
OSUR' s 10-Year Price/Net Cash Range
Min: 2.88   Max: 101.25
Current: 5.6

2.88
101.25
Price/Net Current Asset Value 4.30
OSUR's Price/Net Current Asset Value is ranked higher than
96% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. OSUR: 4.30 )
OSUR' s 10-Year Price/Net Current Asset Value Range
Min: 2.04   Max: 28.26
Current: 4.3

2.04
28.26
Price/Tangible Book 3.20
OSUR's Price/Tangible Book is ranked higher than
85% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.30 vs. OSUR: 3.20 )
OSUR' s 10-Year Price/Tangible Book Range
Min: 1.11   Max: 19.15
Current: 3.2

1.11
19.15
Price/DCF (Projected) 3.20
OSUR's Price/DCF (Projected) is ranked higher than
77% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. OSUR: 3.20 )
OSUR' s 10-Year Price/DCF (Projected) Range
Min: 1.56   Max: 29.48
Current: 3.2

1.56
29.48
Price/Median PS Value 0.80
OSUR's Price/Median PS Value is ranked higher than
94% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. OSUR: 0.80 )
OSUR' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 12.64
Current: 0.8

0.52
12.64
Earnings Yield (Greenblatt) -1.70
OSUR's Earnings Yield (Greenblatt) is ranked higher than
58% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. OSUR: -1.70 )
OSUR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.7   Max: 3.4
Current: -1.7

-1.7
3.4
Forward Rate of Return (Yacktman) 36.32
OSUR's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. OSUR: 36.32 )
OSUR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3   Max: 60.4
Current: 36.32

-3
60.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:EP3.Germany,
OraSure Technologies Inc was formed in May 5, 2000 under Delaware law solely for the purposes of combining two companies, STC Technologies, Inc. and Epitope, Inc. and changing the state of incorporation of Epitope from Oregon to Delaware. The Company is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests that are performed at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. One of its diagnostic products, the OraQuick In-Home HIV Test got approved by the U.S. FDA for sale in the over-the-counter or consumer retail markets in the United States. Its in vitro diagnostic testing is the process of analyzing oral fluid, blood, urine and other bodily fluids or tissue for the presence of specific substances or markers. Through its subsidiary, DNAG, the Company manufacture and sell kits that are used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetics, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. The Company owns rights to trademarks and service marks that are necessary to conduct its business as currently operated. In the United States, it owns the OraSure, Intercept, OraQuick, OraQuick ADVANCE, Histofreezer, OraSure QuickFlu, Q.E.D., Oragene, ORAcollect, OMNIgene, Performagene, PrepIT, HEMAgene, and AUTO-LYTE. The competitors include medical diagnostic companies and specialized biotechnology firms, as well as pharmaceutical companies with biotechnology divisions The Company is subject to other federal and state laws targeting fraud and abuse in the healthcare industry, including false claims laws, marketing conduct laws and laws constraining the sales, marketing and other promotional activities of manufacturers of medical devices by limiting the kinds of financial arrangements, including sales programs, with physicians, hospitals, laboratories and other potential purchasers of medical devices.
» More Articles for OSUR

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: OSUR, DKS, P, MGAM, EROC Jul 09 2012 
Weekly CFO Sells Highlight: OSUR, BMC, EF, HAIN, GCI, VRSK, FIO May 21 2012 
Weekly CFO Sells Highlight: KKD, OSUR, LVLT, OVTI Jul 11 2011 
OraSure Technologies Inc. Reports Operating Results (10-Q) Nov 09 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) May 06 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) Nov 05 2009 
OraSure Technologies Inc. Reports Operating Results (10-Q) Aug 06 2009 
OraSure Technologies Inc. Reports Operating Results (10-Q) May 07 2009 
OraSure Announces Fourth Quarter and Full Year 2008 Financial Results Feb 11 2009 

More From Other Websites
OraSure Technologies Earnings Conference Call Invitation Apr 21 2015
OraSure Technologies Earnings Conference Call Invitation Apr 21 2015
ORASURE TECHNOLOGIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 31 2015
ORASURE TECHNOLOGIES INC Financials Mar 19 2015
ORASURE TECHNOLOGIES INC Files SEC form 10-K, Annual Report Mar 12 2015
Is OraSure Technologies (OSUR) a Great Growth Stock? - Tale of the Tape Mar 04 2015
OraSure Technologies (OSUR): An Off-the-Radar Potential Winner - Tale of the Tape Feb 26 2015
OraSure Technologies to Present at the Cowen & Company 35th Annual Health Care Conference Feb 24 2015
OraSure Technologies to Present at the Cowen & Company 35th Annual Health Care Conference Feb 24 2015
OraSure Technologies to Present at the Raymond James 36th Annual Institutional Investor Conference Feb 23 2015
OraSure Technologies to Present at the Raymond James 36th Annual Institutional Investor Conference Feb 23 2015
OraSure (OSUR) Is in Oversold Territory: What's Next? - Tale of the Tape Feb 10 2015
OraSure reports 4Q loss Feb 04 2015
OraSure reports 4Q loss Feb 04 2015
ORASURE TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 04 2015
DaVita HealthCare Partners Inc Earnings Call scheduled for 5:00 pm ET today Feb 04 2015
OraSure Announces Full-Year and Fourth Quarter 2014 Financial Results Feb 04 2015
Q4 & FY 2014 OraSure Technologies Inc Earnings Release - 4:00 pm ET Feb 04 2015
Zimmer (ZMH) Q4 Earnings Beat, Revenues Miss Estimates - Analyst Blog Jan 29 2015
St. Jude Medical (STJ) Announces Preliminary Q4 Results - Analyst Blog Jan 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK